Navigation Links
Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million
Date:12/18/2007

al law to help support financial aid for undergraduate and graduate students; startup costs for the University's research efforts; construction of new buildings and laboratories and improvements to existing facilities; and for other purposes.

"Essentially, we are converting a potential stream of future royalty revenues from Lyrica into an immediate cash payment," Sunshine explained. "We continue to believe strongly in Lyrica's potential and Northwestern retains a large portion of those royalty rights, but by doing this, we are diversifying the University's investments."

The percentage of the University's interest in the royalty payments that was sold today is not being disclosed.

Morgan Stanley is acting as structuring advisor and Covington & Burling LLP is acting as the legal advisor to Northwestern University for this sale. Goodwin Procter LLP is acting as legal advisor to Royalty Pharma for this sale.

About Northwestern University

Founded in 1851, Northwestern University is a leading private research and teaching university with an enrollment of approximately 8,000 full-time undergraduate students and approximately 7,000 full-time graduate and professional students on campuses in Evanston and Chicago, Illinois.

Northwestern combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. Northwestern provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

For more information, go to: http://www.northwestern.edu

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with a market value of over $4.5 billion. Royalty Pharma currently o
'/>"/>

SOURCE Royalty Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... Most of the 28 million Americans living with untreated ... corrective action could result in the brain actually "forgetting" how ... , Dr. Beyer is senior vice president of HearUSA (Amex: ... hearing aids companies. , "When the brain is insufficiently stimulated ...
... Fla., Oct. 19 Blue Cross and ... statewide Medicare Advantage Regional PPO plan called BlueMedicare Regional ... offerings for Florida,s Medicare eligibles. The BlueMedicare Regional PPO ... Private Fee-for-Service, Part D and Medicare Supplement plans. , ...
... ... the world,s leading manufacturer and distributor of health testing stations and automated blood pressure ... with UnitedHealth Group,s Passport to Health and Well Being at the 2009 AARP Vegas@50+ ... ...
... ... Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration ... 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. ... and hospitals to type and screen blood. Quotient Biodiagnostics was formed ...
... CITY, Kan., Oct. 19 Premier Plastic Surgery of Kansas City, ... has redesigned its extensive website to include a separate section ... and a Plastic Surgery Blog that features breaking news on ... Society for Aesthetic Plastic Surgery, cosmetic surgery for males increased ...
... and men have opposing views on many topics, and it ... pain. According to a new survey of women and men ... leading independent health information source for women, women are more ... have a higher tolerance for pain (76% versus 32%, respectively)(1).In ...
Cached Medicine News:Health News:If Hearing Loss is Not Treated, Brain Can 'Forget' How to Hear and Understand Speech 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 3Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 2Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 3Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 2Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 2Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 4Health News:Women and Men Face Off: Who Can Stand the Pain? 2Health News:Women and Men Face Off: Who Can Stand the Pain? 3
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
Bone Curette, 160 mm...
Bone Currettes...
London Endocervical Curette is a stainless-steel curette for obtaining endocervical samples with minimal effort....
...
Medicine Products: